BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31

BioNexus Gene Lab Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.23+0.03 (+2.23%)

Close on Oct 19, 2026

Market cap: $2.97M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

BioNexus Gene Lab reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in BioNexus Gene Lab's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in BioNexus Gene Lab's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Apr 7, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BGLC.

Revenue growth-67.3% · median 20.8%

Gross margin12.3% · median 35.7%

Operating margin-81.8% · median -19.3%

Net margin-82.4% · median -26.8%

Company	Revenue	Growth
BDSX	$102.94M	+34.5%
CFOR	$76.20M	–
XGN	$71.12M	+20.8%
PSNL	$69.67M	-13.3%
BGLC	$3.13M	-67.3%
YDES	–	–

Company

Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 6
Held by institutions: 0.5%
Auditor: JP CENTURION & PARTNERS PLT
SEC CIK: 1737523

Advertisement
300 × 250